News for AKUS Stock

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases Lilly and Akouos Announce Expiration of Akouos Tender Offer Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting Akouos Reports First Quarter 2022 Financial Results and Provides Business Highlights Akouos to Present at Bank of America 2022 Healthcare Conference Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting Akouos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights Akouos to Participate in Upcoming March Virtual Investor Conferences Akouos Appoints Aaron Tward, M.D., Ph.D., as Chief Scientific Officer Akouos to Present at Cowen 42nd Annual Heath Care Conference Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting Akouos to Participate in Upcoming February Virtual Investor Conferences Akouos to Present at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting Akouos to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference Akouos Reports Third Quarter 2021 Financial Results and Provides Business Highlights Akouos Appoints Stacy Price as Chief Technical Officer Akouos to Present at Jefferies Gene Therapy/Editing Summit Akouos to Present at Upcoming September Virtual Investor Conferences Akouos Reports Second Quarter 2021 Financial Results and Provides Business Highlights Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug Akouos to Present at Upcoming August Virtual Investor Conferences Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates Akouos Presents Nonclinical Data Supporting Future Clinical Development of AK-OTOF and AK-antiVEGF at the American Society of Gene and Cell Therapy 24th Annual Meeting Akouos Appoints Dr. Kathy Reape as Chief Development Officer Akouos to Present at Bank of America 2021 Virtual Healthcare Conference Akouos to Present Nonclinical Data from AK-OTOF and AK-antiVEGF Programs at the American Society of Gene and Cell Therapy 24th Annual Meeting Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss Akouos to Present at 20th Annual Needham Virtual Healthcare Conference Akouos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference Akouos Reports Third Quarter 2020 Financial Results and Provides Business Highlights Akouos to Present at Upcoming October Virtual Investor Conferences Akouos Reports Second Quarter 2020 Financial Results and Provides Business Highlights Akouos Announces Pricing of Initial Public Offering Akouos Announces Closing of Initial Public Offering